Pipeline

    Company Product Type Indication Development stage
    Basilea Pharmaceutica International Ltd. Ceftobiprole Antibacterial drug Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia) 9Marketed
    Summit Therapeutics plc Ridinilazole Antibacterial drug Clostridium difficile infection 7Phase III
    Basilea Pharmaceutica International Ltd. Ceftobiprole Antibacterial drug Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia 7Phase III
    Motif Bio plc Iclaprim Antibacterial drug HABP/VABP 7Phase III
    Motif Bio plc Iclaprim Antibacterial drug ABSSSI 7Phase III
    Polyphor Ltd Murepavadin Antibacterial drug HAP, VAP 7Phase III
    Helperby Therapeutics Ltd HY-005 Antibacterial drug Skin & Soft Tissue MRSA 6Phase II
    Helperby Therapeutics Ltd HY-004 Antibacterial drug Nasal MRSA decolonisation 6Phase II
    NovaBiotics Ltd Lynovex® oral Other Cystic Fibrosis 6Phase II
    NovaBiotics Ltd Novexatin® Non Antibacterial drug Onychomycosis 6Phase II
    MaaT Pharma maaT031 Other Bone and Joint Infectious 6Phase II
    MaaT Pharma MaaT011 Other Acute Myeloid Leukemia 6Phase II
    Destiny Pharma plc XF-73 Antibacterial drug Post-surgical nasal decolonisation 6Phase II
    DA VOLTERRA DAV132 Non Antibacterial drug Prevention of C.difficile infections 6Phase II
    Debiopharm International afabicin (Debio 1450) Antibacterial drug ABSSSI, Bone & Joint Infections (BJIs) 6Phase II
    AntibioTx A/S ATx201 Antibacterial drug Antibiotic - skin infections 6Phase II
    ALLECRA THERAPEUTICS cefepime/AAI101 Antibacterial drug cUTI, cIAI, HAP 6Phase II
    AiCuris Anti-infective Cures GmbH AIC499 - a Superior Gram-negative Resistance Breaker Antibacterial drug Gram-negative resistance breaker 5Phase I
    Combioxin SA CAL02 Non Antibacterial drug Severe infections 5Phase I
    ALAXIA ALX-009 Antibacterial drug Cystic Fibrosis 5Phase I
    NovaBiotics Ltd Lynovex® inhaled Other Cystic Fibrosis 4IND/CTA ready
    Pherecydes Pharma PN 1450 Antibacterial drug MDR infections to Pseudomonas aeruginosa 3Pre-clinical
    Pherecydes Pharma PN 1957 Antibacterial drug MDR infections to Staphylococcus aureus 3Pre-clinical
    Pherecydes Pharma PN 1815 Antibacterial drug MDR infections to Staphylococcus aureus 3Pre-clinical
    Pherecydes Pharma PN 1493 Antibacterial drug MDR infections to Staphylococcus aureus 3Pre-clinical
    Pherecydes Pharma PN 1797 Antibacterial drug MDR infections to Pseudomonas aeruginosa 3Pre-clinical
    Pherecydes Pharma PN 1792 Antibacterial drug MDR infections to Pseudomonas aeruginosa 3Pre-clinical
    Pherecydes Pharma PN 1777 Antibacterial drug MDR infections to Pseudomonas aeruginosa 3Pre-clinical
    DEINOBIOTICS/DEINOVE NBTI Antibacterial drug Gram-negative infections 3Pre-clinical
    Alphanosos W16P0576 Antibacterial drug Infectious skin conditions (eczema, acne, sporiasis, ...), difficult wounds 3Pre-clinical
    Akthelia HO53/HO56 ADP Other Multidrug resistant lung infections including nosocomial infections 3Pre-clinical
    VAXDYN VXD-001 Other Vaccine against untreatable or difficult-to-treat infections, both hospital-acquired infections and community acquired infections, caused by Acinetobacter baumannii 3Pre-clinical
    Phico Therapeutics Ltd SASPject™ PT3.8 Antibacterial drug Serious Pseudomonas Aeruginosa infections where treatment options are limited 3Pre-clinical
    Phico Therapeutics Ltd SASPject™ PT5 Antibacterial drug Serious E.coli infections where treatment options are limited 3Pre-clinical
    Phico Therapeutics Ltd SASPject™ PT4 Antibacterial drug Serious Klebsiella Pneumoniae infections where treatment options are limited 3Pre-clinical
    Helperby Therapeutics Ltd HY-006 Antibacterial drug Pulmonary Cystic Fibrosis 3Pre-clinical
    NovaBiotics Ltd Luminaderm® Antibacterial drug MRSA 3Pre-clinical
    NovaBiotics Ltd Novarifyn® Antibacterial drug Antibacterial Peptide 3Pre-clinical
    NovaBiotics Ltd Nylexa™ Other Resistance breaker 3Pre-clinical
    NovaBiotics Ltd Novamycin® Non Antibacterial drug Invasive Fungal Disease 3Pre-clinical
    Hypharm GmbH HY-133 Antibacterial drug nasal colonization with MRSA 3Pre-clinical
    Auspherix Ltd Novel class of organogold antibiotics Antibacterial drug cUTI 3Pre-clinical
    Centauri Therapeutics Ltd Pseudomonas Aeruginosa specific Inhibitor Other Undisclosed 3Pre-clinical
    Centauri Therapeutics Ltd Broad spectrum Gram negative Inhibitor Other Undisclosed 3Pre-clinical
    NOSOPHARM NOSO-502 Antibacterial drug MDR Enterobacteriaceae infections 3Pre-clinical
    Neem Biotech Ltd NX-AS-401 Non Antibacterial drug Chronic respiratory infections in cystic fibrosis 3Pre-clinical
    Neem Biotech Ltd NX-AS-911 Non Antibacterial drug Chronic wounds 3Pre-clinical
    Motif Bio plc Iclaprim Antibacterial drug Staphylococcus aureus Lung Infections Among Cystic Fibrosis Patients 3Pre-clinical
    Eligo Bioscience EB014 Antibacterial drug Multi-drug resistant Enterobacteriaceae 3Pre-clinical
    Destiny Pharma plc XF-70 Antibacterial drug Bacterial biofilm-infections 3Pre-clinical
    Destiny Pharma plc XF-70 Antibacterial drug Dermal burn wound infections 3Pre-clinical
    Destiny Pharma plc XF-73 Antibacterial drug Hospital pneumonia/ventilator-associated pneumonia (VAP) 3Pre-clinical
    Madam Therapeutics BV SAAP148 Antibacterial drug Diabetic foot ulcers, burns and MRSA carriership 3Pre-clinical
    BioVersys AG Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis Non Antibacterial drug Tuberculosis 3Pre-clinical
    ABAC therapeutics ABAC-39,877 Antibacterial drug Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR 3Pre-clinical
    VIBIOSPHEN Sativa Non Antibacterial drug Pulmonary infection, UTI 3Pre-clinical
    Northern Antibiotics Oy (Ltd) Improved derivatives of polymyxin B Antibacterial drug primary indication, cUTI caused by MDR Gram-negatives 3Pre-clinical
    SetLance srl SET-M33 Antibacterial drug Antimicrobial peptide 3Pre-clinical
    QureTech Bio AB Mtb Tolerance Inhibitor Antibacterial drug MDR Tuberculosis 3Pre-clinical
    ANTABIO S.A.S ANTXXXX Non Antibacterial drug hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) 3Pre-clinical
    BioFilm Pharma BFP001 Other Local - Diabetic Foot Ulcer, Joint & Bone Infections 2Lead opt
    Summit Therapeutics plc Gonorrhoea Antibacterial drug Gonorrhoea infection 2Lead opt
    Omnix Medical OMN6 - A Novel Antibacterial Peptide for IV injection Antibacterial drug One major pathogen directed medical indication - A. baumannii induced Bacteremia or HABP or VABP 2Lead opt
    PhagoMed Biopharma GmbH PhM754 Phages Urinary Tract Infections 2Lead opt
    PhagoMed Biopharma GmbH PhM398 Phages Periprosthetic Joint Infections 2Lead opt
    VAXDYN VXD-003 Other Monoclonal antibodies against hospital-acquired infections and community acquired infections caused by Acinetobacter baumannii 2Lead opt
    VAXDYN VXD-004 Other Vaccine against hospital-acquired infections and community acquired infections caused by Klebsiella pneumoniae. 2Lead opt
    VAXDYN VXD-002 Other Vaccine against hospital-acquired infections and community acquired infections caused by Pseudomonas aeruginosa 2Lead opt
    Mutabilis SAS Antivirulence Gram - Antibacterial drug Preventive treatment for patient at risk of nosocomial infection by Enterobacteriaceae 2Lead opt
    Mutabilis SAS Antivirulence Gram + Antibacterial drug Preventive treatment for patient at risk of nosocomial infection by Staphylococci, Streptococci and Enterococci 2Lead opt
    Mutabilis SAS DAB PO Antibacterial drug Oral inhibitor of Beta-lactamases to be used in combination with a 3rd generation cephalosporine against ESBL/OXA-48/KPC expressing Enterobacteriaceae 2Lead opt
    Mutabilis SAS DAB Antibacterial drug Direct acting antibiotic (IV) against multi-drug resistant enterobacteriaceae (CRE) and/or P. aeruginosa 2Lead opt
    BioVersys AG Anti Virulence in Gram negative bacteria Non Antibacterial drug gram negative infections 2Lead opt
    Polyphor Ltd OMPTA Antibacterial drug HAP, VAP, UTI, IAI, other 2Lead opt
    Polyphor Ltd Murepavadin (inhaled) Antibacterial drug Cystic Fibrosis; Bronchiectasis 2Lead opt
    BioVersys AG Anti-Biofilm for Staphylococcus aureus Non Antibacterial drug systemic 2Lead opt
    QureTech Bio AB Chlamydia Antibacterial drug Genital Chlamydia infection 2Lead opt
    QureTech Bio AB GmP's against VRE and MRSA Antibacterial drug VRE and MRSA 2Lead opt
    ANTABIO S.A.S ANTYYYY Non Antibacterial drug chronic Pseudomonas infections in Cystic Fibrosis patients 2Lead opt
    DEINOBIOTICS/DEINOVE DNV3837 Antibacterial drug C.difficile gastrointestinal infections 1Phase I completed
    BioFilm Pharma BFP102 Other Systemic – Cystic Fibrosis 1Discovery
    BioFilm Pharma BFP101 Other Local - Diabetic Foot Ulcer, Joint & Bone Infections 1Discovery
    BioFilm Pharma BFP002 Other Systemic – Cystic Fibrosis 1Discovery
    MeMed Diagnostics Ltd. Bacterial vs. viral blood test Diagnostic Aid clinicians in differentiating between bacterial and viral infections 1Undisclosed
    NOSOPHARM NOSO-A4 Antibacterial drug P. aeruginosa infections 1Discovery
    Helperby Therapeutics Ltd HY-002 Antibacterial drug Intra-Abdominal Infections 1Phase I completed
    Helperby Therapeutics Ltd HY-001 Antibacterial drug Urinary Tract Infections 1Phase I completed
    Karveel Pharmaceuticals SNP021062 Antibacterial drug Undisclosed 1Undisclosed
    Karveel Pharmaceuticals KVL-## Non Antibacterial drug Undisclosed 1Undisclosed
    Debiopharm International Debio1453 Antibacterial drug N. gonorrhoeae 1Discovery
    DA VOLTERRA DAV121 Non Antibacterial drug Prevention of carbapenem resistance emergence 1Discovery
    QureTech Bio AB Chlamydia Antibacterial drug Trachoma, Chlamydia eye infection 1Discovery

    The stage of development is approximate; please refer to each company’s website for updated information.